Cargando…
Outcomes of Adding Induction Chemotherapy to Concurrent Chemotherapy for Nasopharyngeal Carcinoma Patients with Moderate-Risk in the Intensity-Modulated Radiotherapy Era
BACKGROUND: The aim of this study was to evaluate the efficacy of induction chemotherapy (IC) in nasopharyngeal carcinoma (NPC) patients with moderate-risk treated with intensity-modulated radiotherapy (IMRT). METHODS: We retrospectively assessed 506 patients with T1-2N1M0 or T3-4N0-1M0 NPC (accordi...
Autores principales: | Su, Zhen, Zou, Guo-rong, Tang, Jie, Li, Xiu Yue, Xie, Fang-Yun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7130107/ https://www.ncbi.nlm.nih.gov/pubmed/32280230 http://dx.doi.org/10.2147/TCRM.S241216 |
Ejemplares similares
-
Concurrent Chemotherapy for T4 Classification Nasopharyngeal Carcinoma in the Era of Intensity-Modulated Radiotherapy
por: Cao, Cai-neng, et al.
Publicado: (2015) -
Nomogram Predicting the Benefits of Adding Concurrent Chemotherapy to Intensity-Modulated Radiotherapy After Induction Chemotherapy in Stages II–IVb Nasopharyngeal Carcinoma
por: Liu, Sai-Lan, et al.
Publicado: (2020) -
Gemcitabine/cisplatin induction chemotherapy before concurrent chemotherapy and intensity-modulated radiotherapy improves outcomes for locoregionally advanced nasopharyngeal carcinoma
por: Fangzheng, Wang, et al.
Publicado: (2017) -
T4/N2 classification nasopharyngeal carcinoma benefit from concurrent chemotherapy in the era of intensity-modulated radiotherapy
por: Xie, Ruifei, et al.
Publicado: (2016) -
Propensity score matching analysis of cisplatin-based concurrent chemotherapy in low risk nasopharyngeal carcinoma in the intensity-modulated radiotherapy era
por: Zhang, Lu-Ning, et al.
Publicado: (2015)